Ginsan, a botanic polysaccharide extracted from Panax ginseng, has recently been reported to modulate mucosal immune response. In this study, we investigated the protective effect of Ginsan against fatal Vibrio vulnificus mucosal infection. A lethal dose of V. vulnificus (1.0 × 10 6 CFU/mouse) was nasally inoculated to mice. The bacterial count in the nasal associated lymphoid tissue (NALT) of the mouse was significantly reduced in the Ginsan-treated group. The Ginsan-treated group showed improved survival compared to the control group (100% vs 18%). To elucidate the effect of Ginsan on modulating host immune response, cytokine mRNA expressions involved in mediating inflammation were determined by semiquantitative RT-PCR in the NALTs of the infected mice. Most of the cytokine mRNAs were similarly expressed as the control group. However, COX-1 mRNA expression level was higher in Ginsan-treated group compared to the control group. The protective effect of Ginsan was antagonized by treating with a specific COX-1 inhibitor, SC-560. Thus, these data suggest that the protective effect of Ginsan against V. vulnificus infection is partly mediated by modulating COX-1 expression.
INTRODUCTION
Polysaccharides isolated from botanical sources (mushrooms, algae, lichen and higher plants) have attracted a great deal of attention in biomedical arena because of their broad spectrum of therapeutic properties and relatively low toxicity (1, 2) . Among numerous plant polysaccharides, Ginseng is a slow-root growing herb that has been used medicinally for more than 3000 years by practitioners of oriental medicine (3) . Ginseng products are popularly referred to as "adaptogens" in much of the alternative medicine literature. The term "adaptogen" connotes an agent that purportedly "increase resistance to physical, chemical, and biological stress and builds up general vitality, including the physical and mental capacity for work" (4) .
Ginsan is a soluble polysaccharide extracted from the roots of Panax ginseng. Ginsan functions as an effective biological response modifier; it stimulates NK and T cells, stimulates the production of various cytokines, and induces tumoricidal and antimicrobial activities in macrophages (5) .
Ginsan possesses potent anti-septicemic activity by inducing nitric oxide via proinflammatory cytokine production in stimulated macrophages in vitro (6) .
Among various stresses, bacterial infection is still one of the major threat to living creatures. The primary route for bacterial infection is mostly through the mucosal tissues such as intestine, respiratory tract and genito-urinary tracts.
Mucosal immune system is playing important roles in the first line of physical and immunological defenses against invading pathogens (7).
The components of mucosal defense is multifactorial and can be modulated by a wide range of substances, many of which are classically regarded as inflammatory mediators such as nitric oxide (8) , cytokines (9) and the eicosanoids (10, 11) . Especially, COX-1-dependent prostaglandins were reported to increase the resistance of epithelial cells to injury induced by cytotoxins (12) and topical irritants (10) .
Recently, we have reported that Ginsan suppresses the development of allergic reaction in a murine asthmatic model by modulating COX (13) .
In this report, we have studied the protective effect of Ginsan on mucosal resistance against Vibrio vulnificus, an opportunistic human pathogen causing fulminant septicemia predominantly in patients with chronic liver diseases after invasion of mucosal barriers (14) . Virulent V. vulnificus was intranasally challenged following Ginsan treatment. To enumerate the invaded bacteria, nasal associated lymphoid tissues (NALTs) were collected following the bacterial challenge. To determine the host response, mRNA was isolated from NALT. Marked difference in COX-1 expression was observed in the Ginsan-treated group. When COX-1 was antagonized, the protective effect of Ginsan was lost.
MATERIAL AND METHODS

Bacteria
V. vulnificus CMCP6 was cultured in 2.5% NaCl heart infusion (HI) until late-logarithmic growth phase by shaking (200 rpm) at 37℃. Bacterial cells were harvested by centrifugation and washed twice and resuspended in PBS for nasal inoculation.
Preparation of Ginsan
Ginsan was purified from the ethanol insoluble fraction of the aqueous Panax ginseng extract, as described pre- 
Mouse infection
Female BALB/c mice (6 wks old) were intraperitoneally treated with Ginsan (100 mg/kg) for two days, and control mice were treated with PBS. On the 3rd day, mice were anesthetized with ketamine (100 mg/kg) and intranasally challenged with 1 × 10 6 V. vulnificus CMCP6 in PBS (10 μl). All experiments using mice were followed the guideline approved by the Committee for the Care and Use of Laboratory Animals at Chonnam National University, Korea.
Enumeration of V. vulnificus in mice
The NALTs of the mice were collected 4 hrs after nasal inoculation. The collected NALTs were homogenized in sterile PBS with 0.05% Tween 20 by teasing with needles.
The recovered bacteria were enumerated by plating on HI agar plates.
RT-PCR
Expression levels of mRNA transcripts of inflammatory cytokine genes were quantified using RT-PCR. Total RNA from the NALT was isolated using the TRIzol reagent μM dNTP (Takara, Shiga, Japan), 0.5 U Taq DNA polymerase (Takara), and 0.01 mM of each primer. The primers used in this study are shown in Table 1 . The thermal cycle conditions were 94℃ for 1 min, 55℃ for 30 s, and 72℃
for 30 s for 35 cycles. The PCR products were electrophoresed on 2% agarose gels.
COX-1 inhibitor treatment
SC-560 (Cayman, Ann Arbor, MI, USA) was used to selectively inhibit COX-1 in the mice. BALB/c mice were pretreated with Ginsan (100 mg/kg) for two days, control mice were pretreated with PBS. On the 3rd day, SC-560 (2.5 mg/kg) was orally administered 1 hr before the V.
vulnificus challenge.
RESULTS
Effect of Ginsan-pretreatment on V. vulnificus nasal infection
To examine the protective effect of Ginsan against V.
vulnificus, mice were preatreated with Ginsan (100 mg/kg) for 24 hrs, and then nasally infected with this bacteria. The invaded bacteria in the NALT was enumerated 4 hrs after nasal infection of V. vulnificus. The V. vulnificus count in the NALT was significantly reduced in Ginsan-treated group compared to the control group (Fig. 1A) . Furthermore, when the survival of the mice were observed for 7 days after bacterial inoculation, all of the Ginsan-pretreated mice survived while only 18% of the control group did (Fig. 1B) .
This suggests that Ginsan is protective against nasal V.
vulnificus infection and increases the survival of the host.
Expression of inflammatory cytokine genes in NALT following V. vulnificus infection
To determine the effect of Ginsan on the mucosal inflammatory response to V. vulnificus infection, RT-PCR for the various cytokine genes was performed using RNA extracted from the NALT. While V. vulnificus infection caused significant suppression of COX-1 mRNA expression in the control group, Ginsan-pretreatment did not show this suppression ( Fig. 2A) .
The changes of the COX-1 mRNA expression were examined 1, 2 and 4 hrs after V. vulnificus infection. COX-1 mRNA expression started to decrease 2 hrs after bacterial infection in the control group while it was stably expressed in the Ginsan-treated group (Fig. 2B) . 
DISCUSSION
Ginsan, an effective biological response modifier, has been reported to stimulate NK, macrophages and T cells (5) . Also, Ginsan possesses a potent anti-septicemic activity (6, 16) . Furthermore, Ginsan can suppress the development of allergic reaction in an asthmatic model by modulating mucosal immune responses (13) .
In this study, we examined the protective effect of Ginsan against mucosal V. vulnificus infection. V. vulnificus is a halophilic gram-negative bacterium which causes seafoodrelated fatalities (17) . However, mice infected via oral route, which is the most common natural infection route, are only minimally affected by the pathogen (18) . Intranasal infection of mice has been used as a model for studying immunity to and pathogenesis of Group A Streptococcus (19, 20) . NALT is the mucosa associated lymphoid tissue in the nasal cavity that has functional similarity of Peyer's patch in the gut COX-1 is generally considered a constitutive enzyme and has been implicated in normal cellular homeostasis (22) . However, under certain conditions such as cervical carcinomas, COX-1 expression is upregulated (23) . We have found that Ginsan, which have been popularly used in the oriental medicine, could provide protection against bacterial infection by modulating COX-1 expression. In our previous work with a murine asthma model, the suppressive effect of Ginsan was also mediated by modulating COX expression in the lung (13) which is consistent with our current finding. Further studies are required to determine the protein expression and its products including prostaglandins.
In this study, we have found that the protective effect of Figure 3 . Effect of Ginsan and/or SC-560 pretreatment on V. vulnificus intranasal infection. BALB/c mice were treated with Ginsan (100 mg/kg) for two days, control mice with PBS. On the 3rd day, 1 hr before bacterial challenge, SC-560 (2.5 mg/kg), a specific COX-1 inhibitor, was orally administered. And then mice were nasally inoculated with 1 × 10 6 V. Vulnificus in 10 μl PBS and were sacrificed 4 hrs after infection to enumerate the number of the bacteria in the NALT (*p < 0.05: control vs Ginsan).
Ginsan against bacterial infection is partly mediated by modulating COX-1 expression during V. vulnificus infection.
Further studies are required to find if Ginsan is also protective against other bacterial infection.
